PTAB challenges

Proceedings overview

There is one AIA trial proceeding on file for US Patent 11809431, which is currently pending institution. This means the patent is actively under challenge, and its claims have not yet been tested by a final PTAB decision.

IPR2026-00391 — Teladoc Health, Inc. v. Data Health Partners Inc., Melamed Shahla

• Type: Inter Partes Review
• Filed: 2026-06-05
• Status: Pending. The petition was recently filed and is awaiting a decision on institution.
• Judge panel: The judge panel has not been publicly assigned or published yet, as the proceeding is in its early stages.
• Petition grounds: The specific claims challenged, prior art cited, and statutory bases (§ 102 / § 103) are not yet publicly available in detail, as the petition was only recently filed.
• Institution decision: Not yet issued. The PTAB typically has six months from the filing date of the petition to issue a decision on whether to institute the IPR.
• Final Written Decision (if issued): Not applicable, as the proceeding has not yet been instituted.
• Settlement / termination: No settlement or termination has occurred.
• Appeal: Not applicable, as there is no Final Written Decision to appeal.
• Defensive value: This proceeding indicates that at least one party, Teladoc Health, Inc., believes there are valid grounds to challenge the patent's claims under an IPR. For a defendant, this means the patent is currently being challenged, but no claims have been invalidated or confirmed as patentable by the PTAB yet. The outcome of the institution decision will be the next critical milestone.

Strategic summary

As of today, US Patent 11809431 has one active Inter Partes Review, IPR2026-00391, which was filed by Teladoc Health, Inc. on 2026-06-05. Given the very recent filing date, none of the patent's claims have been canceled, sustained, or fully tested by a final PTAB decision. All claims remain untested in the context of an AIA trial proceeding.

The estoppel landscape is not yet relevant, as no final written decision has been issued. Therefore, the petitioner, Teladoc Health, Inc., and its privies are not yet estopped from raising any grounds. For any other potential defendant, all prior-art grounds remain available for challenge. There are no pattern signals yet, as this is the first and only PTAB proceeding on file for this patent.

Recommended next steps

For parties interested in US Patent 11809431, the most important upcoming milestone for IPR2026-00391 is the institution decision. The PTAB has a statutory deadline of one year from institution to issue a final written decision, but the institution decision itself is typically due within six months of the petition's filing date. Parties should monitor the PTAB E2E system for the institution decision, which will determine whether the IPR proceeds to trial.